Fig. 7: Eosinophil lineage ablation can prevent AML relapse following differentiation therapy. | Nature Communications

Fig. 7: Eosinophil lineage ablation can prevent AML relapse following differentiation therapy.

From: Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy

Fig. 7: Eosinophil lineage ablation can prevent AML relapse following differentiation therapy.The alternative text for this image may have been generated using AI.

a Blood leukemia burden indicating engraftment of control and Gata1 knockout AML246 clones in recipient mice following intravenous transplant of 1 million leukemia cells. b Proportion of mCherry+ AML cells in the peripheral blood of mice transplanted with AML246-Cherry cells from control sgRNA clones (black), Gata1 knockout clones (red), or Xbp1 knockout clones (blue). Bleeds were taken at the time of established disease, when Dox treatment was initiated for the survival analysis shown in c. n = 21, 18, and 12 mice per group respectively over two independent experiments. Mean +/− SD. Relative to control, Gata1 KO p = 0.46 and Xbp1 KO p = 0.7, unpaired two-sided Student’s t-test. c Kaplan–Meier survival analysis of mice from b over 6 months of sustained Dox treatment. Relative to control, Gata1 KO p = 0.016 and Xbp1 KO p = 0.002, Mantel-Cox test. n = 21, 18, and 12 mice per group respectively. Source data are provided as a Source Data file.

Back to article page